Full Breakdown
Inhibrx’s OX40 Immunotherapy Shows Responses in HPV-Positive Head and Neck Cancer
9/9/2026, 11:01:35 AM
Background on OX40-Targeted Cancer Therapies
For the past 15 years, a number of major pharmaceutical companies—including Pfizer, Genentech, GSK, and AstraZeneca—have pursued drugs that activate the immune-system protein OX40 as a strategy against solid tumors. Those efforts have largely ended without clinical success, leaving OX40 an unproven target in oncology.
Trial Findings and Patient Subset
Inhibrx announced on Tuesday that its experimental OX40-directed immunotherapy produced measurable tumor responses in a trial of patients with head and neck cancer. The most notable activity occurred in a small group of participants whose tumors tested positive for human papillomavirus (HPV). The company did not disclose the exact number of responders or the size of the HPV-positive cohort, but emphasized that the signal was stronger in that subset than in the broader study population.
Official Statements & Responses
The company framed the data as an early indication that the therapy could have a niche role for HPV-driven head and neck cancers, while acknowledging that broader efficacy remains to be demonstrated in larger studies.
Verbatim Quotes
- “It’s just really gratifying for us,” — CEO Mark Lappe, said CEO — CEO Mark Lappe, said CEO
Implications and Next Steps
The observed responses suggest that OX40 activation may retain therapeutic potential when applied to specific molecular contexts, such as HPV-positive tumors. Inhibrx plans to further evaluate the immunotherapy in expanded cohorts to confirm efficacy and safety, though timelines for additional trials were not disclosed. If subsequent data corroborate the initial findings, the drug could fill an unmet need for patients with HPV-associated head and neck malignancies, a subgroup that currently has limited targeted treatment options.
